Reunion Neuroscience Inc. (Private) — Reunion Neuroscience dosed the first patient in REKINDLE, a Phase 2 trial evaluating its serotonergic candidate RE104 for adjustment disorder in patients with cancer and other serious medical illnesses.
Topline results are anticipated in 2027. The start follows the company's upsized $133 million Series A closing earlier in September.
Source: reunionneuro.com
For the rest of that week's sector news, read our week in review.